X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.ema.europa.eu/en/documents/overview/dabigatran-etexilate-accord-epar-medicine-overview_en.pdf
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-april-5-2023-55870.pdf
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/ascend-laboratories-llc-issues-voluntary-nationwide-recall-dabigatran-etexilate-capsules-usp-75-mg
https://www.prnewswire.com/news-releases/breckenridge-announces-tentative-approval-of-its-anda-for-dabigatran-etexilate-capsules-generic-for-pradaxa-301528327.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208046
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208046
https://www.prnewswire.com/news-releases/fda-approves-first-oral-blood-thinning-medication-for-children-301316705.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207961
https://www.ema.europa.eu/en/news/no-change-needed-use-direct-oral-anticoagulants-following-ema-funded-study
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208040
https://www.fiercepharma.com/pharma/esc-pfizer-bms-eliquis-adds-to-lead-competitor-topping-french-real-world-data
https://www.clinicaltrialsarena.com/news/boehringer-pradaxa-re-spect-cvt-data/
https://www.fiercepharma.com/marketing/biohaven-touts-oral-cgrp-data-moves-closer-to-regulatory-finish-line-and-maybe-m-a
https://www.thepharmaletter.com/article/safety-and-efficacy-established-for-pradaxa-in-management-of-vte-in-children
https://www.fdanews.com/articles/190097-boehringer-wins-again-as-california-judge-tosses-pradaxa-lawsuit?v=preview
https://www.prnewswire.com/news-releases/fda-provides-full-approval-to-praxbind-specific-reversal-agent-for-pradaxa-300631175.html
https://www.businesswire.com/news/home/20180311005032/en/Findings-Released-Largest-Real-World-Data-Analysis-Non-Valvular
https://www.prnewswire.com/news-releases/boehringer-ingelheim-to-present-new-research-on-pradaxa-and-specific-reversal-agent-praxbind-at-american-college-of-cardiology-scientific-session-300611093.html
http://www.prnewswire.com/news-releases/agente-reversor-de-anticoagulante-oral-e-utilizado-pela-primeira-vez-no-brasil-apos-aprovacao-regulatoria-confirmando-eficacia-e-seguranca-do-medicamento-640605593.html
http://www.prnewswire.com/news-releases/final-phase-iii-study-results-reinforces-safety-and-efficacy-of-praxbind-as-reversal-agent-for-pradaxa-patients-in-emergency-situations-300485601.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208046
http://www.fiercepharma.com/legal/widower-family-face-off-against-bayer-and-j-j-next-xarelto-case
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207984
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208057
http://www.fiercepharma.com/marketing/takeda-s-superheroes-take-fiercemadness-dtc-trophy-final-match-up
http://www.fiercepharma.com/pharma/eliquis-smashes-rivals-xarelto-pradaxa-at-lowering-bleeding-related-costs-real-world-study
http://www.reuters.com/article/us-health-stroke-afib-anticoagulants-idUSKBN16M1ZQ
http://www.fiercepharma.com/marketing/can-xarelto-s-trial-win-artery-disease-help-j-j-keep-rival-eliquis-at-bay
http://www.newsinferno.com/inratio-blood-monitoring-device-recalled-due-to-inaccurate-readings/
http://www.fiercepharma.com/marketing/bms-eliquis-relatively-close-to-snagging-market-lead-from-j-j-s-xarelto-ceo-says
http://www.fiercepharma.com/marketing/j-j-battles-pfizer-bristol-team-for-warfarin-conversions-red-hot-noac-race
http://www.fiercepharma.com/pharma/j-j-s-xarelto-may-cause-more-serious-bleeding-than-bi-s-pradaxa-real-world-study-shows
http://www.fiercepharma.com/marketing/boehringer-s-pradaxa-keeps-its-antidote-edge-as-fda-swats-down-portola-contender
http://www.pmlive.com/pharma_news/portola_rejection_hands_advantage_to_boehringers_pradaxa_1103977
http://www.prnewswire.com/news-releases/boehringer-ingelheim-launches-re-vecto-global-program-to-capture-data-on-praxbind-idarucizumab-usage-in-clinical-practice-300313023.html
http://www.pharmatimes.com/Article/16-05-10/Report_reveals_huge_variation_in_access_to_anti-stroke_drugs.aspx
http://www.fiercepharma.com/pharma/daiichi-caps-layoffs-drive-by-melding-nj-ops-into-one-smaller-hq
http://www.fiercepharma.com/story/acc-latest-lilly-merck-pfizer-novartis-and-more-unveil-key-data/2016-04-04
http://www.fiercepharmaasia.com/story/daiichi-sankyo-spend-big-ma-oncology-more-job-cuts-may-be-coming/2016-04-01
http://www.prnewswire.com/news-releases/boehringer-ingelheim-launches-observational-study-on-management-of-deep-vein-thrombosis-dvt-and-pulmonary-embolism-pe-with-pradaxa-dabigatran-etexilate-mesylate-300239886.html
http://www.bloomberg.com/news/articles/2016-02-25/bayer-quarterly-profit-misses-estimates-on-drop-in-crop-sciences
http://www.fiercepharmamarketing.com/story/hoping-jump-start-lixiana-daiichi-sankyo-taps-merck-european-market-assault/2016-02-22
http://www.europeanpharmaceuticalreview.com/38953/news/industry-news/praxbind-idarucizumab-reimbursed-in-england-ireland-and-wales/
http://www.fiercepharmamarketing.com/story/bms-expects-fast-growing-eliquis-take-lead-over-xarelto-pradaxa/2016-02-03
http://www.fiercepharma.com/story/bristol-myers-immunotherapies-soar-eliquis-haul-tops-charts/2016-01-28
http://www.fiercepharmamarketing.com/story/fishing-market-share-boehringer-ingelheim-casts-new-campaign-pradaxa/2016-01-23
Market Place
Share 
